Stephen Lott, PharmD, MS

Lead Clinical Pharmacist- University of Michigan Prescription Drug Plan
Residency Program Director- PGY1 Managed Care
Adjunct Clinical Instructor- College of Pharmacy
Rotations Offered: Managed care


I am responsible for the management and oversight of pharmacy utilization within the University of Michigan’s prescription drug plan. In this role I manage the plan’s formulary, perform comprehensive drug utilization reviews, and develop and implement clinical programs. 

Pharmacy School Attended: University of Michigan (2012)

Additional Training: 

  • PGY1 Pharmacy Residency: Diplomat Specialty Pharmacy (2013)
  • Masters in Science, Pharmacoeconomics: University of Florida (2015)
  • Bachelors of Science: University of Georgia (2007)

Areas of Interest

Formulary management, pharmacoeconomics, and outcomes research.


Honors & Awards

AMCP Experiential Education Preceptor Award (2020)

AMCP Gold Metal Abstract (2019)


Published Articles or Reviews

  • Gowda C, Lott S, Grigorian M, Carbonari D, Saine M, Trooskin S, Roy J, Kostman J, Urick P, Lo Re V. Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis. 2018 June; 6(5):ofy076. 

  • Andres J, Lott S, Qureshi K. Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data. J Manag Care Spec Pharm. 2018 Jan;24(1):23-28. 

  • Kowdley KV, Sundaram V, Jeon CY, Qureshi K, Latt NL, Sahota A, Lott S, Curry MP, Tsai N, Chaiyakunapruk N, Lee Y, Petersen J, Buggisch P. Eight weeks of Ledipasvir/Sofosbuvir is effective for selected patients with genotype 1 Hepatitis C virus infection. Hepatology. 2017 Apr; 65(4):1094-1103. 

  • Lott S, Burghart K, Burghart P, Bly M, Ellingrod V. The influence of metabolic syndrome, physical activity, and genotype on catechol-o-methyl transferase promoter-region methylation in schizophrenia. Pharmacogenomics J. 2013 Jun; 13(3):264-71. 

  • Warrenfeltz SW, Lott S, Palmer TM, Gray JC, Puett D. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells. Mol Cancer Res. 2008 Nov; (6)11: 1775-85.